Syngenis Labs has successfully raised $4 million in a pre-float funding round aimed at advancing its AI-driven biotech platform, which focuses on RNA and DNA-based medicines. This funding will enable the Perth-based company to enhance its capabilities and position itself within the burgeoning genetic medicine sector in Australia.
The funding round, which saw strong interest from investors, is intended to support the development of Syngenis' integrated ecosystem for RNA and DNA therapeutics. The company plans to create a Good Manufacturing Practice (GMP) facility that will allow it to manufacture clinical-grade oligonucleotide products, an area currently dominated by a few global players. This strategic move is designed to streamline the process from concept to clinical-grade production, offering a competitive edge over other biotech firms that typically focus on narrower aspects of drug development.
Central to Syngenis' approach is its proprietary AI platform, Discovery AI, which not only analyzes biological data but also identifies therapeutic targets and designs candidates for testing. This integrated workflow aims to reduce development timelines and costs, potentially revolutionizing the way therapeutics are developed. Additionally, the company is working on a second AI engine to simulate clinical trials, further enhancing its capabilities in risk assessment and study design.
With the recent funding, Syngenis is poised to expand its operations across multiple business divisions, including clinical research services and whole-genome testing. This diversified strategy minimizes risks and allows the company to capitalize on various revenue streams, positioning it as a critical player in the future of genetic medicine. As global investment in biotechnology grows, Syngenis aims to leverage its comprehensive platform to become a cornerstone of Australia's healthcare innovation landscape.